Emerging Treatments in Neonatal Fungal Infections: Progress and Prospects.

Area of Science:

• Neonatal Medicine
• Mycology
• Infectious Diseases

Background:

• Fungal infections pose significant life-threatening risks to neonates, particularly preterm infants with immature immune systems.
• Candida albicans is the primary fungal pathogen, causing a spectrum of disease from superficial rashes to systemic infections like sepsis and meningitis.
• Congenital cutaneous candidiasis can lead to disseminated infections with high mortality.

Purpose of the Study:

• To review the diagnosis, treatment, and prevention of fungal infections in neonates.
• To highlight the challenges in early diagnosis and the importance of accurate organism identification for targeted antifungal therapy.
• To provide pharmacologic and dosing information for key antifungal agents used in neonatal care.

Main Methods:

• Review of major antifungal agents including amphotericin B, echinocandins, and azoles.
• Discussion of pharmacologic properties and neonatal dosing considerations.
• Emphasis on preventive strategies such as aseptic techniques and clinical monitoring.

Main Results:

• Candida species are the most common cause of neonatal fungal infections, requiring species-specific treatment due to varying susceptibilities.
• Aspergillus and Malassezia are other significant pathogens, with Malassezia often associated with catheter-related fungemia in preterm infants.
• Information on clinical pharmacology of antifungals in neonates is limited, necessitating careful drug selection and dosing.

Conclusions:

• Accurate identification of fungal pathogens is crucial for effective treatment of neonatal fungal infections.
• Antifungal drug selection and dosing in neonates require careful consideration due to limited pharmacokinetic data.
• Stringent aseptic techniques and vigilant clinical monitoring are essential for preventing and managing neonatal fungal infections.